Peter Zage, M.D., Ph.D.

Bio

Dr. Peter Zage is an attending hematologist/oncologist at Rady Children's Hospital-San Diego and an associate professor-in-residence in pediatric oncology at UC San Diego Moores Cancer Center.

Dr. Zage received his bachelor's degree in biology from Johns Hopkins University and earned his medical and doctoral degrees from Columbia University in New York. He then completed a residency in pediatrics at the University of Chicago Children's Hospital and a fellowship in pediatric hematology/oncology at Children's Memorial Hospital (now Lurie Children's Hospital) before starting his first faculty position as an assistant professor at the University of Texas MD Anderson Cancer Center. He was an assistant professor in the Section of Pediatric Hematology/Oncology at Baylor College of Medicine and Texas Children's Cancer Center prior to joining Rady Children's and UC San Diego in 2016.

Dr. Zage is an expert in the treatment of the pediatric solid tumors neuroblastoma and retinoblastoma, and his laboratory is focused on developing novel treatments and identifying novel targets for therapies for children with solid tumors. His primary laboratory projects include studies to better understand the pathways involved in the regulation of growth factor receptor trafficking and degradation in tumor cells and their role in tumor growth and treatment response in addition to studies to identify novel therapeutic targets and novel agents to use in combination with established therapies.

Dr. Zage's laboratory has identified a key role for the ubiquitin ligase UBE4B in the regulation of receptor trafficking in neuroblastoma tumor cells, and he has also identified several promising novel targeted agents that have been translated into early phase clinical trials for children with relapsed and refractory solid tumors.

Publications

Neuroblastoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Bagatell R, Park JR, Acharya S, Aldrink J, Allison J, Alva E, Arndt C, Benedetti D, Brown E, Cho S, Church A, Davidoff A, Desai AV, DuBois S, Fair D, Farinhas J, Harrison D, Huang F, Iskander P, Kreissman S, Macy M, Na B, Pashankar F, Pendyala P, Pinto N, Polites S, Rabah R, Shimada H, Slatnick L, Sokol E, Twist C, Vo K, Watt T, Wolden S, Zage P, Schonfeld R, Hang L

Eflornithine as Postimmunotherapy Maintenance in High-Risk Neuroblastoma: Externally Controlled, Propensity Score-Matched Survival Outcome Comparisons.
Oesterheld J, Ferguson W, Kraveka JM, Bergendahl G, Clinch T, Lorenzi E, Berry D, Wada RK, Isakoff MS, Eslin DE, Brown VI, Roberts W, Zage P, Harrod VL, Mitchell DS, Hanson D, Saulnier Sholler GL

UBE4B interacts with the ITCH E3 ubiquitin ligase to induce Ku70 and c-FLIPL polyubiquitination and enhanced neuroblastoma apoptosis.
Le Clorennec C, Subramonian D, Huo Y, Zage PE

Targeting the RET tyrosine kinase in neuroblastoma: A review and application of a novel selective drug design strategy.
Steen EA, Basilaia M, Kim W, Getz T, Gustafson JL, Zage PE

USP7 Inhibition Suppresses Neuroblastoma Growth via Induction of p53-Mediated Apoptosis and EZH2 and N-Myc Downregulation.
Le Clorennec C, Lee K, Huo Y, Zage PE

A phase II trial of nifurtimox combined with topotecan and cyclophosphamide for refractory or relapsed neuroblastoma and medulloblastoma.
Eslin D, Zage PE, Bergendahl G, Lewis E, Roberts W, Kraveka J, Mitchell D, Isakoff MS, Rawwas J, Wada RK, Fluchel M, Brown VI, Ginn K, Higgins T, BeeravallyNagulapally A, Dykema K, Hanna G, Ferguson W, Saulnier Sholler GL

Identification of a novel gene signature for neuroblastoma differentiation using a Boolean implication network.
Zage PE, Huo Y, Subramonian D, Le Clorennec C, Ghosh P, Sahoo D

Allele-specific expression reveals genes with recurrent cis-regulatory alterations in high-risk neuroblastoma.
Sen A, Huo Y, Elster J, Zage PE, McVicker G

Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion.
Byron SA, Hendricks WPD, Nagulapally AB, Kraveka JM, Ferguson WS, Brown VI, Eslin DE, Mitchell D, Cornelius A, Roberts W, Isakoff MS, Oesterheld JE, Wada RK, Rawwas J, Neville K, Zage PE, Harrod VL, Bergendahl G, VanSickle E, Dykema K, Bond J, Chou HC, Wei JS, Wen X, Reardon HV, Roos A, Nasser S, Izatt T, Enriquez D, Hegde AM, Cisneros F, Christofferson A, Turner B, Szelinger S, Keats JJ, Halperin RF, Khan J, Saulnier Sholler GL, Trent JM

Overview and recent advances in the targeting of medulloblastoma cancer stem cells.
Paul MR, Zage PE

The Anti-Tumor Activity of the NEDD8 Inhibitor Pevonedistat in Neuroblastoma.
Foster JH, Barbieri E, Zhang L, Scorsone KA, Moreno-Smith M, Zage P, Horton TM

Mechanisms of Efficacy of the FGFR1-3 Inhibitor AZD4547 in Pediatric Solid Tumor Models.
Phanhthilath N, Hakim S, Su C, Liu A, Subramonian D, Lesperance J, Zage PE

A subset analysis of a phase II trial evaluating the use of DFMO as maintenance therapy for high-risk neuroblastoma.
Lewis EC, Kraveka JM, Ferguson W, Eslin D, Brown VI, Bergendahl G, Roberts W, Wada RK, Oesterheld J, Mitchell D, Foley J, Zage P, Rawwas J, Rich M, Lorenzi E, Broglio K, Berry D, Saulnier Sholler GL

Is high-risk neuroblastoma induction chemotherapy possible without G-CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factors.
Whittle SB, Smith V, Silverstein A, Parmeter M, Minard CG, Bernhardt MB, Zage PE, Venkatramani R, Nuchtern JG, Heczey A, Russell HV, Shohet JM, Foster JH

Regorafenib is effective against neuroblastoma in vitro and in vivo and inhibits the RAS/MAPK, PI3K/Akt/mTOR and Fos/Jun pathways.
Subramonian D, Phanhthilath N, Rinehardt H, Flynn S, Huo Y, Zhang J, Messer K, Mo Q, Huang S, Lesperance J, Zage PE

Characterization of G-CSF receptor expression in medulloblastoma.
Paul MR, Huo Y, Liu A, Lesperance J, Garancher A, Wechsler-Reya RJ, Zage PE

The Potential Functional Roles of NME1 Histidine Kinase Activity in Neuroblastoma Pathogenesis.
Adam K, Lesperance J, Hunter T, Zage PE

Sociodemographic and clinical characteristics associated with vitamin D status in newly diagnosed pediatric cancer patients.
Aristizabal P, Sherer M, Perdomo BP, Castelao E, Thornburg CD, Proudfoot J, Jacobs E, Newfield RS, Zage P, Roberts W, Martinez ME

The multikinase inhibitor RXDX-105 is effective against neuroblastoma in vitro and in vivo.
Flynn SM, Lesperance J, Macias A, Phanhthilath N, Paul MR, Kim JW, Tamayo P, Zage PE

Novel Therapies for Relapsed and Refractory Neuroblastoma.
Zage PE

Maintenance DFMO Increases Survival in High Risk Neuroblastoma.
Sholler GLS, Ferguson W, Bergendahl G, Bond JP, Neville K, Eslin D, Brown V, Roberts W, Wada RK, Oesterheld J, Mitchell D, Foley J, Parikh NS, Eshun F, Zage P, Rawwas J, Sencer S, Pankiewicz D, Quinn M, Rich M, Junewick J, Kraveka JM

Overview and recent advances in the treatment of neuroblastoma.
Whittle SB, Smith V, Doherty E, Zhao S, McCarty S, Zage PE

CD114: A New Member of the Neural Crest-Derived Cancer Stem Cell Marker Family.
Zage PE, Whittle SB, Shohet JM

The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma.
Whittle SB, Patel K, Zhang L, Woodfield SE, Du M, Smith V, Zage PE

Nifurtimox Is Effective Against Neural Tumor Cells and Is Synergistic with Buthionine Sulfoximine.
Du M, Zhang L, Scorsone KA, Woodfield SE, Zage PE

See the full listing of this physician's publications on PubMed, a service of the National Library of Medicine.

PubMed is a third-party website and not affiliated with Rady Children's Hospital-San Diego.